Radiotherapy and Oncology

Our medical research library holds 9 studies published in Radiotherapy and Oncology (1990–2024). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 7 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Elsevier Scientific Publishers
• Published: 1983 to the present, Ireland
• Language: English
• ISSN: 0167-8140 (print), 1879-0887 (electronic)
• Its record in the NLM Catalog

2020s

• Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma. J.Y. Shin, M. Offin, C.B. Simone, et al. 2024;191:110057. PubMed · Publisher · Free full text

  Abstract

  Background: The objective of this study is to determine the outcomes and toxicities of patients with malignant pleural mesothelioma (MPM) treated with stereotactic body radiotherapy (SBRT).

  Materials And Methods: Data were extracted from an institutional tumor registry for patients diagnosed with mesothelioma and treated with SBRT. Kaplan-Meier and Cox regression analyses were employed to determine local control (LC) and overall survival (OS).

  Results: Forty-four patients with 59 total treated tumors from December 2006 to April 2022 were identified. Fifty-one (86.4 %) cases had oligoprogressive disease (five sites or less). The median prescription dose delivered was 3000 cGy in 5 fractions (range: 2700-6000 cGy in 3-8 fractions). Fifty-one (86.4 %) tumors were in the pleura, 4 (6.8 %) spine, 2 (3.4 %) bone, 1 (1.7 %) brain, and 1 (1.7 %) pancreas. The median follow-up from SBRT completion for those alive at last follow-up was 28 months (range: 14-52 months). The most common toxicities were fatigue (50.8 %), nausea (22.0 %), pain flare (15.3 %), esophagitis (6.8 %), dermatitis (6.8 %), and pneumonitis (5.1 %). There were no grade ≥ 3 acute or late toxicities. There were 2 (3.4 %) local failures, one of the pleura and another of the spine. One-year LC was 92.9 % (95 % CI: 74.6-98.2 %) for all lesions and 96.3 % (95 % CI: 76.5-99.5 %) for pleural tumors. One-year LC was 90.9 % (95 % CI: 68.1-97.6 %) for epithelioid tumors and 92.1 % (95 % CI: 72.1-98.0 %) for oligoprogressive tumors. One-year OS from time of SBRT completion was 36.4 % (95 % CI: 22.6-50.3 %). On multivariable analysis, KPS was the lone significant predictor for OS (p = 0.029).

  Conclusions: Our single-institutional experience on patients with MPM suggests that SBRT is safe with a low toxicity profile and potentially achieve good local control.

  Copyright © 2023 Elsevier B.V. All rights reserved.

2010s

• Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. O. Riesterer, I.F. Ciernik, R.A. Stahel, et al. 2019;138:121-125. Randomized trial PubMed · Publisher

  Abstract

  Postoperative radiotherapy after extrapleural pneumonectomy of malignant pleural mesothelioma was investigated in the randomized phase II trial SAKK17/04. The relapse rate within the high and/or low-dose PTV without previous distant failure was 24%, the isolated in-field-relapse rate within the PTVs was 5% and the distant relapse rate outside of the PTVs was 81%. Clinical outcome was mainly determined by distant disease progression outside of the radiation field.

  Copyright © 2019 Elsevier B.V. All rights reserved.

• The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. M. Ashton, N. O'Rourke, S. Currie, et al. 2017;125(1):1-12. Systematic review PubMed · Publisher · Free full text

  Abstract

  Malignant pleural mesothelioma (MPM) is a devastating disease with limited treatment options and a dismal prognosis. Attempts to employ radical radiotherapy in this disease have been limited by the complex shape of the pleura and the dose restrictions necessitated by the close proximity of radiosensitive structures. Recent shifts towards a 'lung sparing' surgical approach in MPM have further heightened these challenges. The aim of this systematic review is to assess recent advances in radiotherapy planning and delivery, to ascertain how these developments have impacted on the feasibility of delivering photon-based, high-dose radiotherapy with radical intent in MPM. Three electronic databases were searched and a total of 249 articles reviewed. The challenge of generating high quality, practice-defining data for diseases such as MPM was highlighted by the identification of just two randomised studies. Much of the literature consisted of low quality, retrospective data with small cohorts and inconsistent reporting on radiotherapy techniques and dosimetry. Nevertheless, a number of prospective phase II studies were identified to suggest that radical doses of radiotherapy can be delivered safely after a lung sparing procedure in MPM, reporting encouraging survival data and acceptable levels of toxicity.

  Copyright © 2017 Elsevier B.V. All rights reserved.

• Adjuvant radiotherapy for malignant pleural mesothelioma: challenges and pitfalls. G.L. Ceresoli, U. Ricardi, V. Vavassori, et al. 2012;105(2):271. Letter · Comment PubMed · Publisher

• In reply to L. Ceresoli et al. "Adjuvant radiotherapy for malignant pleural mesothelioma: challenges and pitfalls". S. Tonoli, S. Magrini, G. Tassi. 2012;105(2):272. Letter · Comment PubMed · Publisher

• Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. S. Tonoli, P. Vitali, V. Scotti, et al. 2011;101(2):311-5. PubMed · Publisher

  Abstract

  Background And Purpose: To evaluate survival, locoregional control and toxicity in a series of 56 mesothelioma patients treated from May 2005 to May 2010 with post-operative radiotherapy after extrapleural pneumonectomy (EPP) in three Italian Institutions (Brescia, Florence, and Modena).

  Material And Methods: Fifty-six patients treated with adjuvant radiotherapy (RT) after EPP were analyzed. Four patients were treated with 3DCRT, 50 with IMRT and two with helical tomotherapy. Forty-five to 50 Gy in 25 fractions were given to the affected hemithorax and to ipsilateral mediastinum, with a simultaneous integrated boost to the sites of microscopically involved margins up to 60 Gy in 20/56 cases.

  Results: Three year locoregional control (LRC), distant metastasis free (DMF), disease free (DF), disease specific (DSS) and overall survival (OS) rates are 90%, 66%, 57%, 62%, and 60%, respectively.

  Conclusion: Postoperative RT with modern techniques is an effective method to obtain excellent local control and cure rates in mesothelioma patients submitted to EPP.

  Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

• Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity. P. Giraud, A. Sylvestre, S. Zefkili, et al. 2011;101(2):303-6. PubMed · Publisher

  Abstract

  This study evaluated adjuvant helical tomotherapy after extrapleural pneumonectomy ± neo-adjuvant chemotherapy in 24 patients with malignant pleural mesothelioma. Toxicity was judged acceptable despite 2 cases (8%) of suspected grade 5 pneumonitis. With a mean follow-up of 7 months, 5 patients had distant and 2 local and distant failure.

  Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

• Prophylactic irradiation of intervention sites in malignant pleural mesothelioma. M.A. Froment, E. Fréchette, A. Dagnault. 2011;101(2):307-10. PubMed · Publisher

  Abstract

  Background And Purpose: To assess the effectiveness of prophylactic irradiation of intervention track (PIT) to prevent tumor seeding in patients with malignant pleural mesothelioma.

  Materials And Methods: A retrospective review was conducted of 171 patients with a histological diagnosis of pleural mesothelioma with some undergoing prophylactic irradiation of intervention sites.

  Results: Forty-eight patients (28%) received PIT. A majority of patients were followed until death. Thoracoscopy (88%) was the procedure most often performed. Thirty-three percent of patients received chemotherapy. The median dose of PIT was 21 Gy in 3 fractions with electrons or 6 MV photons. The local progression free survival (LPFS) at the intervention site was significantly higher in the PIT group and was not influenced by chemotherapy. At 6 months, LPFS for the intervention sites was 91% with PIT and 74% without PIT (p=0.002). During the follow-up, 6 patients (13%) in the PIT group had tumor invasion of the subcutaneous tissue compared to 40 patients (33%) in the group without PIT (p=0.008).

  Conclusions: This study suggests that PIT in mesothelioma reduces the incidence of procedure tract metastasis. Finally, chemotherapy does not seem to have an influence on the incidence of tract metastasis.

  Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

1990s

• Different imaging methods in the assessment of radiation-induced lung injury following hemithorax irradiation for pleural mesothelioma. P. Maasilta, L. Kivisaari, K. Mattson. 1990;19(2):159-67. PubMed · Publisher

  Abstract

  We have characterized the radiation-induced lung injury on serial chest X-rays, CTs and ultralow field MRs and evaluated the clinical value and cost/benefit ratio of the different imaging methods in 30 patients receiving high-dose hemithorax irradiation for pleural mesothelioma. Lung injury was severe in all patients, but non-specific and essentially as described in text-books. CT provided no clinically relevant, cost effective diagnostic advantage over conventional X-rays in the detection of early or late radiation-induced lung injury, but it was necessary for the evaluation of the disease status of mesothelioma. The possible advantage of MR over CT could not be evaluated and needs further studies. Optimal time-points for imaging CTs or MRs to detect early radiation-induced lung injury following high dose hemithorax irradiation were during the latter part of treatment or very shortly after the end of irradiation. Late injury or irreversible fibrosis developed rapidly after 6 months and was clearly documented by chest X-rays. We recommend serial chest X-rays at 1-2, 6 and 12 months following radiotherapy as a cost-effective method for the detection of radiation-induced lung injury with additional CTs to document the stage of mesothelioma, when needed.

Browse every journal in the library or the library by type of article, or return to medical research.